TD Cowen, Health Care
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston,
Skye Bioscience to Present at TD Cowen Health Care Conference
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation.
Snowflake (NYSE:SNOW) was in the spotlight on Friday as TD Cowen said recent partner checks were “constructive” ahead of the ...
TD Cowen lowered the firm’s price target on Freshpet (FRPT) to $141 from $174 and keeps a Buy rating on the shares post the Q4 report.
Oliver Chen, TD Cowen senior retail analyst, joins 'Money Movers' to discuss Wall Street's reaction to Walmart's quarterly ...
Charles Schwab (NYSE:SCHW – Get Free Report) was upgraded by equities researchers at TD Cowen from a “hold” rating to a “buy” ...
TD Cowen raised the firm’s price target on Analog Devices (ADI) to $280 from $260 and keeps a Buy rating on the shares. The firm said they ...
The recommendation change came from Susquehanna Research one day after Lam's research day. Susquehanna now feels Lam is worthy of a positive (i.e., buy) tag; previously, it had flagged the stock as ...
TriNet Group (NYSE:TNET – Get Free Report) was downgraded by equities research analysts at TD Cowen from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Ratings ...
TD Cowen analyst Derrick Wood keeps a Buy rating on Salesforce (CRM) with a $400 price target ahead of the company’s Q4 report on February 26.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback